Rezolute reports second quarter fiscal 2025 financial results and provides business update

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (hi), receives breakthrough therapy designation and orphan drug designation

RZLT Ratings Summary

RZLT Quant Ranking